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Description of the evidence collection method 
These guidelines were drafted after the preparation of 
19  questions relevant to the diagnosis and treatment 
of chronic myeloid leukemia. The questions were structured 
using the PICO (Patient-Intervention-Comparison-Outcome) 
methodology, thus enabling the creation of strategies to 
search for evidence (Appendix 1) in the main scientific 
electronic databases (MEDLINE/PubMed, Embase, LILACS/
SciELO, Cochrane Library, PreMEDLINE via OVID). A manual 
search for evidence in dissertations and theses was also 
conducted (Digital Library of Theses and Dissertations [BDTD] 
of Instituto Brasileiro de Informação em Ciência e Tecnologia 
[IBICT]). Evidence was selected by critical evaluation using 
discriminatory instruments (scores) according to the cate-
gory of question: diagnosis (QADAS) or therapy (Jadad for 
randomized clinical trials and the Newcastle-Ottawa scale 
for non-randomized studies). After identifying potential studies 
to support recommendations, they were selected based on the 
strength of evidence and grade of recommendation calculated 
using the Oxford classification (available at www.cebm.net). 
Degree of recommendation and strength of evidence 
A:  Experimental or observational studies of higher consis ten cy.
B:  Experimental or observational studies of lesser consis-
tency.
C:  Case reports (non-controlled studies).
D:  Opinions without critical evaluation based on consensus, 
physiological studies, or animal models.
Objectives
To set parameters for clinical diagnosis, to evaluate severity, and 
to standardize treatment, maintenance, and monitoring options 
for chronic myeloid leukemia (CML) patients. The target audience 
of these guidelines is hematologists, aiming at contributing to 
decision-making during the diagnosis and treatment of CML.
Introduction
The Guidelines Project is a joint initiative of the Brazilian 
Medical Association and the Federal Medical Council that aims 
to reconcile medical information to standardize practices in 
order to help reasoning and decision-making during treatment. 
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Recommendation
The p190(e1a2) transcript is associated with a reduced thera-
peutic response; there is controversy as to whether there is 
difference in response between the p210 e13a2(b2a2) and 
p210 e14a2(b3a2) transcripts. 
3. Upon diagnosis, do the Philadelphia 
chromosome and 9q deletion have a prognostic 
significance?
There is no difference in survival between CML patients with 
the chromosome 9q deletion on interferon alpha treatment 
and those without this deletion. However, there is a reduction 
in the survival of patients with the deletion spanning the 
BCR-ABL junction compared to those without this deletion. The 
survival rate is 44% higher in chronic phase patients submitted 
to bone marrow transplantation who do not have the deletion 
(number needed to treat [NNT]: 2)8 (B). There is evidence that 
the disease-free survival, overall survival, and cytogenetic 
response is reduced in CML patients with the chromosome 
9q34 deletion under treatment with interferon alpha9,10 (B).
A comparison of first-generation (imatinib) or second-
generation (nilotinib or dasatinib) tyrosine kinase inhibitors 
in the treatment of CML patients with chromosome 9 deletion 
shows that there is no difference in overall survival, disease-
free survival, or in cytogenetic response between patients 
with and without the chromosome 9 deletion over a two-year 
follow-up11,12 (B). There is, however, evidence that there is a 
reduction in survival of patients with derivative chromosome 
9 deletions13 (B).
The ABL deletion on the derivative chromosome 9 (15.1%) in 
CML patients reduces disease-free survival; the BCR deletion 
reduces overall survival, and combined ABL and BCR deletions 
reduce the overall and disease-free survival14 (B). There is 
evidence that only the ABL deletion reduces the survival time 
and the duration of the chronic phase15 (B).
Over a five-year follow up, imatinib-treated CML patients 
with variant Philadelphia chromosome translocations do not 
demonstrate differences in overall survival, disease-free survival, 
progression-free survival, complete hematological response, 
cytogenetic response, or molecular response compared to patients 
without variant Philadelphia chromo some translocations16,17 
(B). Other studies have shown that Philadelphia chromosome 
mosaicism increases mortality by 3.3 years in 21% (number 
needed to harm [NNH]: 5), and that translocation variations 
reduce the cytogenetic response18,19 (B) in CML patients.
Recommendation
Despite controversy on whether chromosome 9q, BCR 
deletions, and variant Philadelphia chromosome result in 
worse prognoses, there is evidence of reduction in overall 
and disease-free survival, as well as in therapeutic response 
of CML patients treated with interferon alpha or first- and 
second-generation tyrosine kinase inhibitors. ABL deletion 
reduces the overall and disease-free survival of these patients. 
The presence of variant Philadelphia chromosome and mosai-
cism also appear to worsen the prognosis in CML. 
Data contained in this manuscript were prepared and are 
recommended by the Brazilian Association of Hematology, 
Hemotherapy, and Cell Therapy. Even so, all possible practices 
should be evaluated by the physician responsible for treatment 
depending on the patient’s setting and clinical status.
1. What are the diagnostic criteria for chronic 
myeloid leukemia?
The diagnosis of CML is based on blood count (leukocytosis 
and often also thrombocytosis), and on differential blood count 
(immature granulocytes, metamyelocytes, myeloblasts, and 
basophilia). Diagnosis depends on the identification of the 
Philadelphia chromosome (22q-), resulting from the translocation 
t(9;22)(q34;q11) and/or BCR-ABL gene rearrangement in 
peri pheral blood or bone marrow cells. In some cases, the 
Philadelphia chromosome cannot be detec ted and the diagnosis 
is made by molecular methods. Most diagnoses are made in 
the chronic phase, and the clinical course has three stages: the 
chronic phase, the accelerated phase, and the blast crisis. The 
accelerated phase is defined as the presence of 1% to 19% blasts 
in the blood or bone marrow, basophils > 20%, thrombocytosis or 
thrombocytopenia not related to therapy, and clonal evolution 
in cytogenetic evaluation. The blast crisis is characterized by 
blasts > 20% or extramedullary blast proliferation1-3 (D).
Recommendation
The diagnosis of CML depends on the identification of the 
Philadelphia chromosome and/or the BCR-ABL rearrangement.
2. Is there any difference in the prognosis  
of CML patients with p210 e13a2(b2a2)  
and e14a2(b3a2) or p190(e1a2) rearrangements?
The prevalence of the BCR-ABL p190(e1a2) transcript in 
CML patients is 1%. This rearrangement is associated with 
decreased therapeutic response to tyrosine kinase inhibitors, 
with complete hematologic response attained in 30% of cases, 
complete cytogenetic response in 20% of cases (three to 
18 months), and major molecular response in 10% of cases. 
Progression to other phases (accelerated or blast crisis) occurs 
in 60% of chronic phase patients4 (C).
The response of treatment-naïve CML patients to treatment 
with imatinib is different for the b3a2(e14a2) and b2a2(e13a2) 
transcripts. In 12 months of treatment, patients with the 
b3a2(e14a2) transcript have a 29% increase in complete cytogenetic 
response, which is faster, and a longer disease-free survival5 (B). 
In CML patients on imatinib treatment for six months, the 
number of b2a2(e13a2) transcripts is lower when compared 
to the number of b3a2(e14a2) transcripts, suggesting greater 
sensitivity of the b2a2(e13a2) transcripts to Imatinib and 
consequently better prognosis6 (B).
Imatinib treatment in chronic-phase CML patients with the 
BCR-ABL b2a2(e13a2) transcript has better results compared 
to those with the b3a2(e14a2) transcript, with a 31% increase 
in the major cytogenetic response and a smaller number of 
BCR-ABL transcripts7 (B).
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4. Do cytogenetic abnormalities in addition to 
the Philadelphia chromosome (Ph) at diagnosis 
have a prognostic significance?
In CML patients under treatment with second-generation 
(dasatinib or nilotinib) tyrosine kinase inhibitors or imatinib, 
the presence of additional chromosomal abnormalities reduces 
disease-free and overall survival by five years20 (B).
The presence of additional chromosomal aberrations 
in CML patients under treatment with nilotinib increases 
mortality  by 28% due to disease progression (NNH: 4). 
Additionally, mortality is increased by 38% at two years 
in chronic phase patients with additional chromosomal 
aberrations (NNH: 3)21 (B). 
Aberrations reduce the survival time of these patients22,23 
(B). The presence of additional chromosomal aberrations 
increases mortality by 36% (NNH: 3) and reduces the mean 
overall survival of CML patients submitted to stem cell 
transplantation24 (B). 
CML-related disease-free and overall survival at five years is 
different in patients with cytogenetic changes compared to those 
without them. The presence of major cytogenetic aberrations 
(major route), such as a second Philadelphia chromosome, 
trisomy 8, isochromosome 17q, or trisomy 19, reduces disease-
free and overall survival at five years by 40%25 (B). 
Recommendation
The presence of additional chromosomal aberrations at 
diagnosis (major route) reduces the overall and disease-free 
survival, and increases mortality by 36% to 40%.
5. Are the criteria of the World Health 
Organization comparable to other criteria  
to classify chronic myeloid leukemia phases 
(chronic, accelerated, and blast crisis phases)?
The use of the World Health Organization (WHO) classification 
of CML stratifies patients into chronic, accelerated, and blast 
crisis phases at ratios of 77.8%, 15.5%, and 6.7%, respectively26 
(C). Appropriate classification allows for the establishment of 
adequate response estimates27 (D).
In the treatment of CML patients with imatinib, there is no 
difference in the overall classification of patients in the chronic, 
accelerated, and blast crisis phases between the standard 
method and the WHO criteria. The distribution of patients 
according to the standard classification is approximately 60% 
in the chronic phase, 28% in the accelerated phase, and 12% in 
blast crisis. Although there is no significant difference between 
the classifications, 6% of patients classified in the chronic 
phase by the standard classification were reclassified into the 
accelerated phase (WHO). Similarly, 9% of patients classified 
in the accelerated phase and 7% in the chronic phase were 
reclassified as blast crisis according to the WHO criteria28 (B).
There are little differences between the M. D. Anderson 
Cancer Center (MDACC), International Bone Marrow Transplant 
Registry (IBMTR), and WHO classifications and definitions of 
the accelerated phase of CML, particularly with respect to the 
percentages of blasts and platelets (Table 1)29 (D):
Recommendation
The WHO classification for the chronic, accelerated, and 
blast crisis phases of CML is similar to the IBMTR and MDACC 
classifications.
6. Is it important to define risk in chronic 
myeloid leukemia patients using the Sokal  
and Hasford scores?
The Sokal score can be determined using an online calculator 
(www.pharmacoepi.de). The score takes into account the size 
of the spleen (in centimeters) palpable below the left costal 
border (LCB), the platelet count, the percentage of blasts, and 
the age. A result < 0.8 corresponds to low risk; from 0.8 to 1.2, 
intermediate risk; and > 1.2, high risk. The Sokal score has a 
predictive value in CML patients treated with imatinib, where 
molecular and cytogenetic responses are higher in low-risk 
patients. High-risk, intermediate-risk and low-risk patients 
who achieve cytogenetic response within 12 months have 
probabilities of survival of 90%, 94%, and 97%, respectively. The 
Hasford score considers the age, the percentage of eosinophils, 
basophils, platelet count, spleen size in centimeters, and 
percentage of blasts; the patient has low risk when the result 
is < 780, intermediate risk when the result is between 780 and 
1,480, and high risk when > 1,480. The five-year survival 
rate corresponding to each risk group is 76%, 55%, and 25%, 
respectively30 (A) 31 (D).
The Sokal score predicts response to treatment of CML patients 
with interferon alpha therapy; the high-risk, inter mediate-risk, 
and low-risk groups comprise 48%, 29%, and 23% of the cases with 
mean survival times of 45, 76, and 105 months, respectively. The 
ten-year survival is 8%, 28% and 34%, respectively32 (B). 
After the introduction of imatinib treatment, the Sokal score 
identified an increase in the five-year survival rate of low-risk 
CML patients of 11%, of 40% in intermediate-risk patients, and 
of 38% in high-risk patients33 (B). Moreover, it is known that 
high-risk patients are more likely to evolve to the accelerated 
phase or blast crisis on imatinib therapy34 (A). The Sokal score 
is also inversely related to cytogenetic response in high-risk 
patients35 (B), as there is a 30.4% reduction in the cytogenetic 
response36 (B).
The Hasford score identifies patients at low risk with a 
probability of survival at nine years of 41%; intermediate risk, 
Characteristic MDACC IBMTR WHO
Blasts (%) > 15 > 10 10-19
Platelets < 100 No response < 100 or > 1000
IBMRT, International Bone Marrow Transplant Registry; MADACC, 
M.D. Anderson Cancer Center; WHO, World Health Organization.
Table 1 − Classifications and definitions of the 
accelerated phase of chronic myeloid leukemia. 
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with probability of 0.16%; and high-risk, with a zero probability 
at nine years. The Sokal and Hasford scores classify 23% and 
9% of all patients as high-risk, respectively. Patients with 
low or intermediate risk who achieve complete hematologic 
response have probabilities of survival of 51% and 23%, 
respectively; those without complete hematologic response 
have probabilities of 26% and 12%, respectively. High-risk 
patients who achieve cytogenetic response have prognoses 
similar to those at low risk37 (B). Of the different groups 
as classified by Hasford, 57% of low-risk patients present 
complete cytogenetic response and 27% of intermediate-risk 
and high-risk patients achieve complete cytogenetic 
response38 (B).
The Hasford and Sokal scores predict complete hematologic 
responses mainly in low-risk patients39 (B). 
Recommendation
The Sokal and Hasford scores are prognostic predictors of CML 
patients.
7. Is imatinib better than second-generation 
tyrosine kinase inhibitors as a first-line treatment 
of chronic phase chronic myeloid leukemia?
A comparison between dasatinib (100 mg) and imatinib 
(400 mg) as a first-line treatment in chronic-phase CML 
patients demonstrates that complete hematologic response is 
11% higher, cytogenetic response is 11% higher, and molecu lar 
response is 18% higher with dasatinib (NNT: 9)40 (B). The two-
year follow-up of these patients upholds the higher beneficial 
effect of dasatinib compared to imatinib41 (B).
Initial treatment of chronic-phase CML patients using 
nilotinib (300 mg or 400 mg twice daily) compared to imatinib 
(400 mg once daily) increases the molecular response at 
12 months by 22% (NNT: 5), increases the cytogenetic response 
by 15% (NNT: 7), and reduces the likelihood of progression to 
the accelerated phase and blast crisis42 (A). In the two-year 
follow up, the effect of nilotinib increases the molecular 
response by 27% (NNT: 4), the cytogenetic response is 10% 
higher than imatinib (NNT: 10); this difference is 5% lower than 
the evaluation at 12 months. The reduction in progression is 
maintained43 (A).
Recommendation
Dasatinib and nilotinib provide greater benefits than imatinib 
in the first-line treatment of chronic-phase CML patients 
regarding molecular, cytogenetic, and hematologic responses, 
as well as disease progression.
8. Does the time between diagnosis and start 
of treatment with imatinib have prognostic 
significance?
In chronic-phase CML patients, imatinib treatment may be 
started after diagnosis (early), or may be started after 24 months 
of treatment with interferon (late), leading to different results 
regarding toxicity and effectiveness. Early treatment reduces 
the risk of grade I and II adverse effects by 52% (NNT: 2), and 
grade III and IV adverse effects by 81% (NNT: 1), although it 
increases the risk of neutropenia and thrombocytopenia by 
5% (NNH: 20). After one year of follow-up in patients who have 
not achieved complete cytogenetic response, early treatment 
produces a reduction in the risk of grade I adverse events by 
3% (NNT: 33); grade II, by 8% (NNT: 12); and grades III and IV, by 
7% (NNT: 14)44 (B).
In early treatment, there is a 16% increase in complete 
cytogenetic response (NNT: 7), a 2% reduction in the risk of 
relapse (NNT: 50), and a 15% increase in disease-free survival 
(NNT: 7)44 (B).
There is reduction in the risk of non-hematological 
adverse events with early treatment, including weight gain 
(11%), periorbital edema (12%), rash (9%), diarrhea (11%), and 
infections (19%), but there is increased risk of hemorrhage (5%), 
and bone pain (8%)44 (B).
Imatinib treatment after diagnosis of chronic phase CML 
(early treatment) increases the likelihood of major molecular 
response by 20% (NNT: 5), and increases the likelihood of 
response maintenance at 30 months by 36% (NNT: 3), compa-
red to beginning treatment one year after diagnosis (late 
treatment). After one year of imatinib treatment, the likelihood 
of loss of or not achieving molecular response is 58% lower in 
early treated patients (NNT: 2)45 (B).
Treatment with 400 mg of imatinib produced higher major 
and complete cytogenetic response rates compared to the 
interferon and cytarabine combination in initial chronic-phase 
CML patients (87.1% vs. 34.7%) and higher survival free of 
progression to the accelerated phase and blast crisis (96.7% 
vs. 91.5%; p-value < 0.001)30 (A). 
Recommendation
Imatinib treatment of chronic-phase CML patients should be 
started as early as possible after diagnosis.
9. Does the cytogenetic evaluation have  
an impact on prognosis?
The identification of CML patients on imatinib treatment with 
cytogenetic clonal evolution provides some information on the 
prognosis, which depends on the disease phase. The presence 
of this change in the chronic and accelerated phases is not 
associated with a different cytogenetic response; however, 
it reduces the survival rate. Cytogenetic response after three 
months of treatment is an independent prognostic factor. The 
absence of complete or partial response is associated with 
lower survival rates46 (B).
In CML patients on imatinib treatment, the presence of a 
cytogenetic response increases four-year survival by 23% 
(NNT: 4) and disease-free survival by 38% (NNT: 3)47 (B).
After six years of treatment with imatinib, 77% of the 
patients were still with stable complete cytogenetic response, 
with a survival rate of 91%; 44% of the patients progressed to 
the accelerated phase or blast crisis48 (B).
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The expected loss of cytogenetic response in the first year of 
imatinib treatment is 0.6%, and the mortality rate at two years 
of patients who achieved response is reduced. The estimated 
eight-year mortality rate of these patients is 4.8%49 (B).
For CML patients unresponsive to imatinib and thus treated 
with second-generation tyrosine kinase inhibitors (dasatinib 
and nilotinib), the cytogenetic response confers 20% greater 
survival (NNT: 5); when associated with hematologic response, 
the increase in the survival rate is of 42% (NNT: 2)50 (B).
The presence of minor or major cytogenetic response in 
chronic-phase CML patients under treatment with second-
generation tyrosine kinase inhibitors increases event-free 
survival, overall survival, and disease-free survival by approxi-
mately 25% (NNT: 4)51 (B). 
Recommendation
The cytogenetic evaluation of patients under tyrosine kinase 
inhibitors treatment can predict the prognosis by complete or 
partial response, whether or not associated to other factors.
10. Does molecular evaluation by quantitative 
real-time polymerase chain reaction have 
an impact on prognosis?
The BCR-ABL/ABL ratio is almost always below 2% in chronic-
phase CML patients who attain a cytogenetic response on 
imatinib treatment. Patients with the BCR-ABL/ABL ratio 
below 0.0001% are regarded as having complete molecular 
response. For patients who lose the cytogenetic response 
within 24 months (2.5%), the mean value of the ratio is 0.12%. 
Some relapsed patients evolve with disease progression (15.4%) 
with BCR-ABL/ABL ratios that vary from 0.3% to 0.0075%, 
which, within the usefulness of quantitative real-time PCR 
in molecular evaluation, defines the extremes of positive or 
negative residual disease, but with a great variability in the 
mean52 (B).
In CML patients investigated using quantitative PCR, the 
estimated major molecular response rate at 60 months is 67.1% 
and the cytogenetic response is 81.7%. Regarding the outcomes 
event-free survival, including transformation to accelerated 
phase and blast crisis; death from any cause; loss of adherence 
to treatment; or loss of cytogenetic response, there are more 
patients who attain molecular response than those who do not. 
Patients with major molecular response have better survival 
than patients with complete cytogenetic response who do not 
achieve major molecular response53 (B).
The estimated molecular response obtained by PCR 
analysis in CML patients treated with imatinib also allows for 
a comparison with hematologic and cytogenetic responses 
over time. Thus, in an 18-month follow-up, the molecular, 
cytogenetic and hematologic responses were 79%, 83%, and 
93%, respectively54 (B). 
Cytogenetic progression (loss of response, clonal evolution, 
20% increase in the Philadelphia clone) may occur in 13% of 
CML patients on imatinib treatment in two years of follow-up. 
At the time of progression, none of these patients presented 
major molecular response (reduction > 3-log in BCR-ABL). 
Thus, there is a suggestion that the cytogenetic analysis 
should be restricted to cases that do not attain or that lose 
molecular response as measured by quantitative real-time 
PCR55 (B).
To evaluate changes in the levels of BCR-ABL transcripts 
as prognostic markers by quantitative real-time PCR, 
monitoring during four years demonstrates major molecular 
response (> 3-log reduction) and predicts higher disease-free 
survival rates. A minimal increase of 0.5-log predicts shorter 
relapse-free survival. Loss of molecular response (< 2.5-log 
reduction) also defines reduction in disease-free survival. A 
complete molecular response (PCR undetectable) corresponds 
to an increased disease-free survival56 (B). 
Recommendation
The prognosis (survival, relapse, progression) of CML patients 
on imatinib treatment can be predicted using quantitative 
real-time PCR.
11. Can cytogenetics be replaced by quantitative 
PCR to monitor chronic myeloid leukemia 
patients taking tyrosine kinase inhibitors who 
attain complete cytogenetic response?
There is a correlation between the levels of transcripts in 
the bone marrow and peripheral blood at three months of 
treatment and the success in obtaining a molecular response 
at six months57 (B). 
The comparison among quantitative real-time PCR (qPCR), 
cytogenetics, and fluorescence in situ hybridization (FISH) to 
monitor response to treatment using tyrosine kinase inhibitors 
in CML patients demonstrates the following correlations and/
or concordances: qPCR in the bone marrow and peripheral 
blood; cytogenetics in the bone marrow, FISH in peripheral 
blood, and qPCR in peripheral blood58 (B). 
Despite the correlation between qPCR and cytogenetic analy-
sis, other prognostic factors may be associated with molecular 
or cytogenetic responses, affecting the outcomes during tyrosine 
kinase inhibitors treatment of chronic-phase CML patients. 
This allows formultivariate analyses that estimate the impact 
of the interaction of prognostic factors present in the medical 
practice, but in multivariate analysis, only the three-month 
cytogenetic response is predictive of the response at six months 
and disease-free survival at two years57 (B). 
Relapse occurs at 24 months in 2.5% of patients who 
have obtained cytogenetic response, and these patients may 
expe rience disease progression to the accelerated phase 
and blast crisis. The correlation between PCR analysis and 
cytogenetic response may contain a range of values that 
hamper interpretation and thus do not favor the substitution 
of methods52 (B).
Three-monthly monitoring using qPCR may provide the 
prognostic data needed for decision-making in CML patients, 
thereby reducing the need of bone marrow aspirations. The 
reasons why PCR monitoring is sufficient include: the level 
of log reduction in the BCR-ABL/ABL ratio correlates with 
cytogenetic response; in the 12-month follow-up, no patient 
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has disease progression without an indication of risk by qPCR 
(half-log increase or five-fold increase in the previous value 
of the BCR-ABL/ABL ratio); and no patient has cytogenetic 
progression in the presence of molecular response55 (B).
Recommendation
qPCR in peripheral blood can be used as the examination of 
choice to monitor chronic-phase CML patients on imatinib 
treatment. Cytogenetics is a fundamental option for monitoring 
that may be used in association with qPCR or that may be 
reserved for cases where either there is no molecular response 
or the molecular response was lost.
12. What is the treatment of choice  
for chronic-phase chronic myeloid leukemia 
patients resistant to imatinib 400 mg?
In chronic-phase CML patients resistant to imatinib 400 mg 
(lack of complete hematological response at three months, 
lack of cytogenetic response at six months, or lack of major 
cytogenetic response at 12 months of treatment), a comparison 
of treatment with dasatinib 140 mg and an increase in the dose 
of imatinib (800 mg) demonstrated the following results for 
dasatinib: complete hematologic response increases in 11% 
of patients (NNT: 9), complete cytogenetic response increases 
by 23% (NNT: 4), and major molecular response increases by 
12% (NNT: 8). Moreover, there were 27% and 15% reductions 
in the risk of swelling and water retention, respectively, 
with dasatinib 140 mg. However, the risk of neutropenia and 
thrombocytopenia increases by 22% (NNH: 5) and 42% (NNH: 2), 
respectively59 (B). These results persisted at 18 months of 
follow-up, with an increase in disease-free survival60 (B).
The treatment of these patients (chronic phase CML resistant 
to imatinib) with dasatinib 100 mg/day compared to 140 mg/
day leads to a similar clinical response in six months and two 
years of follow-up (complete hematologic response, cytogenetic 
response, and disease-free survival); however, the risk of pleural 
effusion is reduced by 9% (NNT: 11), of thrombocytopenia, by 
15% (NNT: 7) and of discontinuity of treatment61,62 (A).
The response rate of chronic-phase CML patients on 
nilotinib treatment (400 mg twice a day) is no different to 
patients resistant or intolerant to imatinib (600 mg/day). The 
lack of response to imatinib (hematologic or cytogenetic) 
predicts absence of response to nilotinib63 (B). Patients who 
attain a response with nilotinib remain with 96% to 98% of 
response (hematologic or cytogenetic) and disease-free survival 
at six months of follow-up64 (B). The mean time to obtain a 
complete hematologic response is 2.8 months and complete 
cytogenetic response is 3.2 months; disease-free survival and 
overall survival at 24 months areestimated at 64% and 87%, 
respectively65 (B). Patients resistant to imatinib or dasatinib 
treatment attain 79% complete hematologic response and 24% 
complete cytogenetic response at 12 months66 (C).
In chronic-phase CML patients resistant to imatinib and 
dasatinib, treatment with bosutinib (500 mg/day) produces 
complete hematological and cytogenetic responses in 62% and 
31% of the cases, respectively. Patients resistant to imatinib 
and nilotinib treatment achieve complete hematological and 
cytogenetic responses in 75% and 35% of cases, respectively. 
In cases of resistance to imatinib or dasatinib, the likelihood 
of maintaining response, disease-free survival, and overall 
survival from 12 months onwards are 27%, 32.4%, and 72.9%, 
respectively. In patients resistant to imatinib and nilotinib 
treated with bosutinib, the odds of maintaining response, 
disease-free survival, and overall survival from 12 months 
onwards are 22.2%, 44.4%, and 77.7%, respectively67 (B). 
Recommendation
Chronic-phase CML patients, who are resistant to imatinib at a 
dose of 400 mg, should be treated with dasatinib (100 mg/day), 
nilotinib (800 mg/day), or bosutinib (500 mg/day). 
13. Are there differences in the toxicity profiles 
of second-generation tyrosine kinase inhibitors 
(dasatinib and nilotinib)?
The difference in adverse effects between imatinib with 
nilotinib or dasatinib is expressed as NNT when these latter 
two drugs produce a reduction in the risk of adverse effects, and 
as NNH when the risk of a particular adverse effect increases.
The use of nilotinib (at any dose) as first-line therapy of 
patients with newly diagnosed CML reduces the rates of nausea 
(NNT: 8), diarrhea (NNT: 7), vomiting (NNT: 6), muscle spasm 
(NNT: 6), edema (NNT: 11), and neutropenia (NNT: 3) when 
compared to imatinib. However, the rates of rash (NNH: 4), 
headache (NNH: 8), pruritus (NNH: 8), and alopecia (NNH: 11) 
increase, and there are also increases in liver enzymes 
(NNH: 2), total bilirubin (NNH: 2), and glucose (NNH: 5)42 (A).
When nilotinib is given as second-line therapy to 
chronic-phase CML patients, cardiotoxicity can occur, with 
increases in the QTc (1% of cases) and thrombocytopenia (29% 
of cases)64 (B).
In a comparison of dasatinib and imatinib as first-line 
therapy for CML, the main non-hematological adverse effects 
including nausea (NNT: 9), myositis (NNT: 8), and water 
retention (NNT: 4) are reduced with dasatinib. However, there 
are increases in pleural effusion in 10% (NNH: 10), thrombo-
cytopenia in 9% (NNH: 11), and cardiotoxicity in 0.4%40 (B).
As second-line therapy in chronic-phase CML patients, 
dasatinib causes an increase in the rates of pleural effusion 
(NNH: 6), neutropenia (NNH: 5), thrombocytopenia (NNH: 2), 
dyspnea (NNH: 6), and headache (NNH: 7)59 (B).
Recommendation
Regarding most expected adverse effects using this class of 
medication, dasatinib and nilotinib have similar results but 
with slight differences in degree. However, nilotinib appears 
to cause more hepatotoxicity and dasatinib causes more water 
retention (pleural effusion). 
14. Does adherence to imatinib treatment have 
prognostic impact?
CML patients on imatinib treatment who have suboptimal 
response are less adherent to treatment (do not take the 
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medication) than patients with optimal response. Patients 
treated for more than 12 months who have complete cyto-
genetic response also have better compliance than those with 
partial cytogenetic response. There is no difference in the 
hematologic response between adherent and non-adherent 
patients68 (B).
There is a direct correlation between adherence (< 90% 
or > 90%) of CML patients to imatinib treatment and the 
likelihood of higher molecular response at six years (an 
increase in 66.1% of response in adherence > 90%). When 
adherence is less than 80%, there is no molecular response. 
Patients who need to increase the dose of imatinib have a 
12.8% reduction in adherence69 (B). 
In the treatment of CML with imatinib, adherence < 85% 
increases the risk of loss of complete cytogenetic response by 
34.9% (NNH: 3). None of the patients with adherence > 95% lost 
cytogenetic response. Patients with adherence level < 85% who 
never attained molecular response, have low adherence as a 
predictor of loss of cytogenetic response. Adherence of < 85% 
reduces the disease-free survival by 37% (NNH: 3). Adherence 
of more than 85% confer prognoses similar to those for major 
molecular response patients70 (B).
The five-year disease-free survival in chronic-phase CML 
patients who adhere to imatinib treatment is 16.9% higher 
than for non-adherent patients. Non-compliance reduces 
the possibility of complete cytogenetic response by 18% 
(NNH: 6). The greatest cause of imatinib treatment cessation 
(29.6% of the cases) is related to nonadherence. Complete 
cytogenetic response is correlated to adherence to treatment, 
with a reduction in the response in noncompliant patients 
by 20%71 (B).
Recommendation
Adherence to imatinib treatment is directly correlated to 
the probability of molecular and cytogenetic responses and 
disease-free survival.
15. Are prior cytogenetic response to imatinib 
and performance status prognostic factors 
for response to second-line inhibitors in 
imatinib-resistant patients?
The best cytogenetic response (0% positive Philadelphia 
chromosome) during treatment with imatinib is predictive 
of response to dasatinib and nilotinib, with an increase in 
cytogenetic response by 21% when compared to the maximum 
range of Philadelphia chromosome rate between 1% and 94%, 
and 66.8% when compared to no cytogenetic response during 
treatment with imatinib, i.e. Philadelphia > 95%51 (B).
The response to second-line tyrosine kinase inhibitors of 
imatinib-resistant CML patients is associated with some other 
prognostic factors, which are: 1. low-risk Sokal: 25.5% increase 
in cytogenetic response and 27.0% in disease-free survival; 
2. percentage of positive Philadelphia chromosome at the 
beginning of treatment < 95%: 43.8% increase in the cytogenetic 
response and 27.3% in disease-free survival; 3. Time to 
therapeutic failure of imatinib < six months: 37.2% increase in 
cytogenetic response, 24.3% increase in overall survival rate, 
and 13.8% increase in progression-free survival51 (B).
The prognosis of treatment using second-line tyrosine 
kinase inhibitors (nilotinib or dasatinib) in imatinib-resistant 
CML patients can be predicted by prior cytogenetic response 
(imatinib), giving an estimated 37% increase in disease-free 
survival at three years and in the cytogenetic response 
at one year. A performance status (European Cooperative 
Oncology Group [ECOG]) of “0” at the beginning of treatment 
with  second-line inhibitors predicts an 18% increase in 
disease-free survival and a 32% increase in overall survival at 
three years72 (B). 
Other prognostic factors may be associated with response 
to treatment with nilotinib or dasatinib, such as: age higher 
than 55 years old with a 24% reduction in cytogenetic response 
at one year, a 20% reduction in disease-free survival at 
three years, and a 6% reduction in overall survival at three 
years; > 90% Philadelphia chromosome-positive metaphases 
at start of treatment with second-line inhibitor with a 30% 
reduction in the cytogenetic response and a 21% reduction in 
disease-free survival72 (B).
Recommendation
Information related to cytogenetic response and performance 
status (ECOG) should be used to assess prognosis on 
starting second-line treatment with nilotinib or dasatinib 
in previously imatinib-resistant CML patients. Additionally, 
age and cytogenetic response prior to treatment with 
second-generation tyrosine kinase inhibitors should be taken 
into account.
16. When is it necessary to make an analysis  
of BCR-ABL mutations in chronic myeloid 
leukemia patients on treatment with tyrosine 
kinase inhibitors?
BCR-ABL mutations are associated with 100% resistance to 
Imatinib treatment in accelerated phase CML patients, and in 
79% of chronic-phase patients73 (B).
The presence of BCR-ABL mutations increases the risk 
by 52% of chronic-phase CML patients evolving to the 
accelerated phase or blast crisis within nine months (NNH: 
2). These mutations, especially P-loop mutations, also reduce 
the time free of disease progression and survival of these 
patients74 (B). 
In the follow-up of CML patients, BCR-ABL mutations occur 
at different times in patients on treatment with imatinib, and 
are correlated with lower survival rates. For patients in the 
early phase of the disease, mutations are associated with 
increases in transformation to the accelerated phase (32%) 
and blast crisis (16%), and with a reduction in the complete 
cytogenetic response (24%). Regardless of the stage of the 
disease, mutations reduce hematologic response75 (B). 
BCR-ABL mutations in CML patients on imatinib treatment 
predict, within approximately 20 months, loss of complete 
cytogenetic response and progression to the advanced stages 
of the disease76 (B).
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Hematologic and cytogenetic responses are similar in patients 
with and without BCR-ABL mutations on treatment with tyrosine 
kinase inhibitors (dasatinib and nilotinib). Moreover, disease-free 
survival and overall survival are not significantly different 
between these two groups of patients77 (B).
In the four-year follow-up of chronic-phase CML patients, 
the time from the beginning of imatinib treatment to the 
progression of the disease to the accelerated phase or blast 
crisis is shorter in patients with mutations than those without 
mutations. The overall survival of patients with mutations and 
those without mutations is 10 and 51 months respectively, 
but this varies according to the type of mutation: P-loop 
(13 months), T315I (nine months), and without mutation 
(51 months)78 (B).
Among chronic-phase CML patients under nilotinib 
treatment, the two-year overall survival is reduced by 38% in 
the presence of BCR-ABL mutations. In addition, the presence 
of mutations is associated with a 34% reduction in the 
cytogenetic response21 (B).
T315I mutations occur more often in patients treated 
with dasatinib. The presence of mutations during nilotinib 
or dasatinib treatment is predictive of a worse prognosis in 
these patients20 (B).
Recommendation
BCR-ABL mutations should be investigated in CML patients 
resistant to tyrosine kinase inhibitors (suboptimal response or 
failure) regardless of the stage, since their presence predicts 
the greater risk of resistance and shorter survival. 
17. Does the diagnosis of mutations guide  
the choice of treatment in Imatinib-resistant 
patients?
In imatinib-resistant CML patients, mutations can assist 
in the choice of second-generation inhibitors, nilotinib or 
dasatinib. An evaluation of the sensitivity of mutations to 
inhibitors in in vitro studies (IC50) defines three groups of 
sensitivity (low, intermediate, and high concentrations) 
of the mutation to: dasatinib (IC50 < 3 nM, 3-60 nM, and 
> 60 nM) and nilotinib (IC50 < 50 nM, 50-500 nM and > 500 nM) 
with the worst case scenario (resistance) corresponding to 
high concentrations77 (B).
Hematologic and cytogenetic responses at one year are 
significantly lower in patients with mutations and in the 
chronic phase, particularly for mutations with intermediate 
IC50 (25% and 25%, respectively) compared to low IC50 (96% 
and 54%, respectively). In the accelerated phase there is 
also a reduction in the cytogenetic response for mutations, 
with 10% reduction in intermediate IC50 and 31% reduction 
in low IC50
77 (B). In the chronic phase, disease-free survival 
and overall survival are lower in patients with mutations 
with high IC50 (0% and 75%, respectively), when compared 
to mutations with low IC50 (78% and 100%, respectively)
77 (B). 
T315I mutation is associated with high IC50 (resistance), but 
there is no difference in its distribution comparing dasatinib 
and nilotinib77 (B). 
Other specific mutations associated with high IC50 in the 
chronic phase of CML treated with dasatinib are: T315I/A, 
F317L/I/V/C, and V299L79-81 (B), and with nilotinib: T315I, 
Y253H, E255K/V, and F359V/C82 (B). The G250E mutation 
also has an impact on resistance common to both forms of 
treatment 81 (B).
Mutations associated with resistance to dasatinib, such as 
V299L, T315A, and F317I, may be sensitive to nilotinib, while 
mutation V299L may be resistant to bosutinib82,83 (B).
Complete cytogenetic response subsequent to treatment 
using dasatinib or nilotinib is lower in patients with resistant 
mutations (0%) compared to patients with other mutations or 
without mutations (41% and 49%, respectively). The survival 
of chronic-phase CML patients when resistant mutations are 
detected is 0% compared with 51% and 45% in patients with 
other mutations or without mutations, respectively84 (B).
Recommendation
The identification of mutations, especially resistant mutations, 
can assist in the choice of the tyrosine kinase inhibitor, 
allowing for the selection of the therapeutic option that will 
provide the best response. 
18. How should monitoring of chronic myeloid 
leukemia patients taking tyrosine kinase 
inhibitors be performed?
Wang et al. stated that monitoring of chronic-phase CML 
patients for BCR-ABL during imatinib treatment can be 
achieved with PCR in peripheral blood (BCR-ABL/ABL ratio), 
correlating this with the result obtained through the usual 
cytogenetic study of bone marrow, which identifies responsive, 
partially responsive, and unresponsive patients in respect to 
BCR-ABL/gene control of up to 0.08%, of 0.08% to 10%, and of 
above 11%, respectively85 (B). 
In a randomized study, 1,106 CML patients were treated 
with interferon and imatinib as initial treatment. All patients 
who achieved cytogenetic remission performed qPCR for 
BCR-ABL. The results were expressed in terms of the logarith-
mic reduction in relation to the median level of transcripts in 
30 newly-diagnosed patients. Patients who achieved complete 
cytogenetic remission and at least a 3-log reduction in the 
level of transcripts had progression-free survival of 100% at 
24 months, compared to 95% for those with complete cyto-
genetic remission and less than a 3-log reduction in the level of 
transcripts, and 85% for patients without complete cytogenetic 
response86 (B). 
Thus, this form of monitoring also allows for the identi-
fication of the two-year progression-free survival with the low 
values of transcripts86,57 (B). 
Using samples from 38 international centers, a study valida-
ted the use of an international scale of BCR-ABL values that 
established 0.1% as a 3-log reduction87 (B). 
It is possible to stratify patients through PCR during the 
three-year follow-up of patients whose indexes reflect 
in crea ses, stability, reduction, or even loss of cytogenetic 
response52 (B). 
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Plasma imatinib levels are significantly higher in patients 
with molecular and cytogenetic responses compared to patients 
without response. The level that differentiates molecular 
response and lack of response with the greatest accuracy (77% 
sensitivity and 71% specificity) is 1,002 ng/mL88 (B).
The use of FISH to monitor CML patients on imatinib 
treatment enables the use of peripheral blood to identify 
cytogenetic response. A positive result points to the absence 
of cytogenetic response, and a negative result identifies its 
presence. The association with PCR allows the molecular 
response to be monitored. In the study by Reinhold et al., 
the estimated cytogenetic and molecular responses at five 
years were 81.7% and 67.1%, respectively53 (B). However, the 
comparison between the results of FISH using peripheral blood 
leukocytes and the cytogenetics of the bone marrow may not 
establish an appropriate correlation in 89 (B).
Identifying the existence and occurrence of mutations in 
tyrosine kinase inhibitors treatment of CML patients allows 
for the estimate of the prognosis and guides the treatment. 
High-performance liquid chromatography is a practical and 
sensitive method that identifies mutations, which can be used 
for clinical monitoring of patients90 (B). 
Some mutations can be identified by direct sequencing 
during the follow-up of patients including: T315T, T315I, F317L, 
V339L, M351T, E355G, Y253F, F359V, among others; these are 
associated with different responses to available inhibitors. A 
31% reduction in the overall survival of patients with mutations 
was identified in the three-year follow-up73 (B). 
Recommendation
The monitoring of CML patients treated with tyrosine kinase 
inhibitors can be accomplished by bone marrow cytogenetics 
and qPCR for the BCR-ABL gene in peripheral blood, thereby 
allowing an estimation of prognosis and the definition 
of therapeutic strategies. Mutational analysis should be 
performed in patients with suboptimal response or loss of 
response to tyrosine kinase inhibitors.
19. When should bone marrow transplantation 
be indicated for chronic myeloid leukemia 
patients?
Imatinib may be used as treatment for relapse after allogeneic 
hematopoietic stem cell transplantation, the prevalence of 
which ranges from 40% to 70% at five months. In the chronic 
phase, the cytogenetic and hematologic response rates obtai-
ned and survival at nine months are 58%, 84%, and 100%, 
respectively91,92 (B). Imatinib has become first-line treatment 
in the chronic phase of CML, demonstrating increased survival 
when used before bone marrow transplant93 (B). 
Due to the lower cost, resistance to imatinib, or advanced 
stages of the disease (accelerated phase and blast crisis), some 
case series have been reported with comparative results or 
in association to imatinib, demonstrating similar disease-free 
survival, overall survival, and cardiotoxicity94 (C). The previous 
use (before transplantation) of imatinib in patients in advanced 
stages of CML produces hematological response in 73% and 
cytogenetic response in 40% of patients, and three years after 
the transplant, 66.7% of patients have complete molecular 
response95 (C). 
In a prospective study, Jiang et al. compared accelerated 
phase patients treated either with imatinib (n = 87) or allogeneic 
transplantations (n =  54). In their study, a multivariate 
analy sis established hemoglobin < 10.0, blasts in peripheral 
blood < 5%, and disease duration of less than 12 months as 
independent risk factors for survival. High-risk (two risk factors 
or more) or intermediate-risk patients (one risk factor) had 
better overall survival and progression-free survival with 
allogeneic transplant. No difference was observed in low-risk 
patients96 (B).
The mortality of CML patients on imatinib treatment 
associated with hematopoietic stem cell transplant is 9.7%, 
and the relapse rate is 5.0% at one year97 (C). 
Despite the new options in imatinib-resistant patients, 
such as dasatinib or nilotinib, non-comparative case series 
that associate tyrosine kinase inhibitors and transplant are 
still being performed98 (C).
Data are still limited for the pediatric population, but the 
results with imatinib are similar to those for adults. Millot 
et al. published their experience with 44  children with 
newly-diagnosed CML treated with imatinib. With a median 
follow-up of 31 months, the estimated progression-free 
survival at 36  months was 98%. The rates of complete 
cytogenetic response and major molecular response at 
12 months were 61% and 31%, respectively. About 30% of the 
children dis continued the use of medication, mainly due to 
lack of effec tiveness. Tyrosine kinase inhibitors adversely 
affect the growth of children, and this aspect should be 
monitored99 (B).
Regarding transplantation, researchers reported the 
results of a prospective study involving 200 CML children and 
teenagers treated by allogeneic transplantation according to 
donor availability. The probability of survival at five years was 
87 ± 11% for matched related donors, 52 ± 9% for matched 
unrelated donors, and 45 ± 16% for unmatched donors. The 
likelihood of relapse at five years was 20 ± 12%100 (B). 
Recommendation
Bone marrow transplantation is a therapeutic option to treat 
CML, but should be reserved for cases resistant to tyrosine 
kinase inhibitor treatment and patients in the advanced 
stages of the disease after an initial course of tyrosine kinase 
inhibitors. 
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